English

NUCRYST Pharmaceuticals Corp.

EDGAR

Quarterly report (10-Q) · filed 2009-11-16

19 filing records in this dataset, filed from 2006-03-23 to 2009-11-16. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

20.9 million USD

2008 · USD

Exact inputs and evidence

Revenue: 20907000 USD Source

Operating margin

-29.3%

2008 · %

Exact inputs and evidence

Operating Income: -6126000 USD Source
Revenue: 20907000 USD Source

Cash and cash equivalents: 13.4 million USD 2009-09-30 Source
Exact value

13414000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-4 thousand USD

2008-10-01 – 2009-09-30

Exact inputs and evidence

Net income: -2971000 USD · 2008-01-01 – 2008-12-31 Source
Net income: -3963000 USD · 2008-01-01 – 2008-09-30 Source
Net income: -1076000 USD · 2009-01-01 – 2009-03-31 Source
Net income: -413000 USD · 2009-04-01 – 2009-06-30 Source
Net income: 493000 USD · 2009-07-01 – 2009-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2009-11-16.

Financial data available through: 2008-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2008-12-31
Operating income: 6 of 11 periods available· newest 2008-12-31
Net income: 6 of 11 periods available· newest 2008-12-31
operating cash flow: No compatible figures in this window
Capital expenditure: 6 of 11 periods available· newest 2008-12-31
Total assets: 5 of 11 periods available· newest 2008-12-31
Total liabilities: 1 of 11 periods available· newest 2008-12-31
Current assets: 1 of 11 periods available· newest 2008-12-31
Current liabilities: 3 of 11 periods available· newest 2008-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2008-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-30.5%

Prior period

USD 30.09 million

2007-01-01 – 2007-12-31
Current period

USD 20.91 million

2008-01-01 – 2008-12-31

Exact inputs and evidence

20907000 − 30092000 = -9185000 USD

30092000 USD · 2007-01-01 – 2007-12-31
Inspect prior input Prior source
20907000 USD · 2008-01-01 – 2008-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · NUCRYST Pharmaceuticals Corp. · 2008-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Year-over-year change in Revenue: -9185000 USD Concept: fundies:Revenue Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 20907000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#19308 Input fundies:Revenue: 30092000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#19308
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 1.05 million

Prior period

−USD 4.02 million

2007-01-01 – 2007-12-31
Current period

−USD 2.97 million

2008-01-01 – 2008-12-31

Exact inputs and evidence

-2971000 − -4021000 = 1050000 USD

-4021000 USD · 2007-01-01 – 2007-12-31
Inspect prior input Prior source
-2971000 USD · 2008-01-01 – 2008-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · NUCRYST Pharmaceuticals Corp. · 2008-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Year-over-year change in Net income: 1050000 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -2971000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#20548 Input fundies:NetIncome: -4021000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#20548
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-37.2%

Prior period

USD 1.92 million

2007-01-01 – 2007-12-31
Current period

USD 1.21 million

2008-01-01 – 2008-12-31

Exact inputs and evidence

1206000 − 1920000 = -714000 USD

1920000 USD · 2007-01-01 – 2007-12-31
Inspect prior input Prior source
1206000 USD · 2008-01-01 – 2008-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · NUCRYST Pharmaceuticals Corp. · 2008-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Year-over-year change in Capital expenditure: -714000 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1206000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#21448 Input fundies:CapitalExpenditure: 1920000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#21448
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Operating cash flow.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2008 2008-01-01 – 2008-12-31

Revenue USD 20.91 million 100% of revenue
Operating costs Derived USD 27.03 million 129% of revenue
Operating income −USD 6.13 million −29% of revenue
Tax, interest and other Derived −USD 3.16 million −15% of revenue
Net income −USD 2.97 million −14% of revenue

Cash

Operating cash flow Unavailable An input is unavailable.
Capital expenditure USD 1.21 million 5.8% of revenue
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2003 Operating loss: operating costs were 115% of revenue.
2004 13%82%
2005 Net loss: net income was −11% of revenue.
2006 Operating loss: operating costs were 146% of revenue.
2007 Operating loss: operating costs were 104% of revenue.
2008 Operating loss: operating costs were 129% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2003 2003-01-01 – 2003-12-31	11404000	13089000 Derived	-1685000	616000 Derived	-2301000	Unavailable	Source 2003-01-01 – 2003-12-31: 11404000 USD Inspect Revenue Open source 2003-01-01 – 2003-12-31: -1685000 USD Inspect Operating Income Open source 2003-01-01 – 2003-12-31: -2301000 USD Inspect Net Income Open source 2003-01-01 – 2003-12-31: 1265000 USD Inspect Capital Expenditure Open source
2004 2004-01-01 – 2004-12-31	24682000	20234000 Derived	4448000	3100000 Derived	1348000	Unavailable	Source 2004-01-01 – 2004-12-31: 24682000 USD Inspect Revenue Open source 2004-01-01 – 2004-12-31: 4448000 USD Inspect Operating Income Open source 2004-01-01 – 2004-12-31: 1348000 USD Inspect Net Income Open source 2004-01-01 – 2004-12-31: 1817000 USD Inspect Capital Expenditure Open source
2005 2005-01-01 – 2005-12-31	23636000	22780000 Derived	856000	3497000 Derived	-2641000	Unavailable	Source 2005-01-01 – 2005-12-31: 23636000 USD Inspect Revenue Open source 2005-01-01 – 2005-12-31: 856000 USD Inspect Operating Income Open source 2005-01-01 – 2005-12-31: -2641000 USD Inspect Net Income Open source 2005-01-01 – 2005-12-31: 3784000 USD Inspect Capital Expenditure Open source
2006 2006-01-01 – 2006-12-31	24369000	35459000 Derived	-11090000	-591000 Derived	-10499000	Unavailable	Source 2006-01-01 – 2006-12-31: 24369000 USD Inspect Revenue Open source 2006-01-01 – 2006-12-31: -11090000 USD Inspect Operating Income Open source 2006-01-01 – 2006-12-31: -10499000 USD Inspect Net Income Open source 2006-01-01 – 2006-12-31: 4978000 USD Inspect Capital Expenditure Open source
2007 2007-01-01 – 2007-12-31	30092000	31434000 Derived	-1342000	2679000 Derived	-4021000	Unavailable	Source 2007-01-01 – 2007-12-31: 30092000 USD Inspect Revenue Open source 2007-01-01 – 2007-12-31: -1342000 USD Inspect Operating Income Open source 2007-01-01 – 2007-12-31: -4021000 USD Inspect Net Income Open source 2007-01-01 – 2007-12-31: 1920000 USD Inspect Capital Expenditure Open source
2008 2008-01-01 – 2008-12-31	20907000	27033000 Derived	-6126000	-3155000 Derived	-2971000	Unavailable	Source 2008-01-01 – 2008-12-31: 20907000 USD Inspect Revenue Open source 2008-01-01 – 2008-12-31: -6126000 USD Inspect Operating Income Open source 2008-01-01 – 2008-12-31: -2971000 USD Inspect Net Income Open source 2008-01-01 – 2008-12-31: 1206000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 20.9M 2008

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Revenue	11404000	Revenue: 11404000 Open source
20042004-12-31	Revenue	24682000	Revenue: 24682000 Open source
20052005-12-31	Revenue	23636000	Revenue: 23636000 Open source
20062006-12-31	Revenue	24369000	Revenue: 24369000 Open source
20072007-12-31	Revenue	30092000	Revenue: 30092000 Open source
20082008-12-31	Revenue	20907000	Revenue: 20907000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-30.5% 2008

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20032003-12-31	Year over year	No prior comparable period	Revenue: 11404000 Open source
20042004-12-31	Year over year	116.4%	Revenue: 24682000 Open source Revenue: 11404000 Open source
20052005-12-31	Year over year	-4.2%	Revenue: 23636000 Open source Revenue: 24682000 Open source
20062006-12-31	Year over year	3.1%	Revenue: 24369000 Open source Revenue: 23636000 Open source
20072007-12-31	Year over year	23.5%	Revenue: 30092000 Open source Revenue: 24369000 Open source
20082008-12-31	Year over year	-30.5%	Revenue: 20907000 Open source Revenue: 30092000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -29.3% 2008

Net margin -14.2% 2008

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20032003-12-31	Operating margin	-14.8%	Operating Income: -1685000 Open source Revenue: 11404000 Open source
20042004-12-31	Operating margin	18%	Operating Income: 4448000 Open source Revenue: 24682000 Open source
20052005-12-31	Operating margin	3.6%	Operating Income: 856000 Open source Revenue: 23636000 Open source
20062006-12-31	Operating margin	-45.5%	Operating Income: -11090000 Open source Revenue: 24369000 Open source
20072007-12-31	Operating margin	-4.5%	Operating Income: -1342000 Open source Revenue: 30092000 Open source
20082008-12-31	Operating margin	-29.3%	Operating Income: -6126000 Open source Revenue: 20907000 Open source
20032003-12-31	Net margin	-20.2%	Net Income: -2301000 Open source Revenue: 11404000 Open source
20042004-12-31	Net margin	5.5%	Net Income: 1348000 Open source Revenue: 24682000 Open source
20052005-12-31	Net margin	-11.2%	Net Income: -2641000 Open source Revenue: 23636000 Open source
20062006-12-31	Net margin	-43.1%	Net Income: -10499000 Open source Revenue: 24369000 Open source
20072007-12-31	Net margin	-13.4%	Net Income: -4021000 Open source Revenue: 30092000 Open source
20082008-12-31	Net margin	-14.2%	Net Income: -2971000 Open source Revenue: 20907000 Open source
20032003-12-31	Free cash flow margin	Not reported	Revenue: 11404000 Open source Capital Expenditure: 1265000 Open source
20042004-12-31	Free cash flow margin	Not reported	Revenue: 24682000 Open source Capital Expenditure: 1817000 Open source
20052005-12-31	Free cash flow margin	Not reported	Revenue: 23636000 Open source Capital Expenditure: 3784000 Open source
20062006-12-31	Free cash flow margin	Not reported	Revenue: 24369000 Open source Capital Expenditure: 4978000 Open source
20072007-12-31	Free cash flow margin	Not reported	Revenue: 30092000 Open source Capital Expenditure: 1920000 Open source
20082008-12-31	Free cash flow margin	Not reported	Revenue: 20907000 Open source Capital Expenditure: 1206000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Operating cash flow	Not reported	No source recorded
20042004-12-31	Operating cash flow	Not reported	No source recorded
20052005-12-31	Operating cash flow	Not reported	No source recorded
20062006-12-31	Operating cash flow	Not reported	No source recorded
20072007-12-31	Operating cash flow	Not reported	No source recorded
20082008-12-31	Operating cash flow	Not reported	No source recorded

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Free cash flow	Unavailable	Capital Expenditure: 1265000 Open source
20042004-12-31	Free cash flow	Unavailable	Capital Expenditure: 1817000 Open source
20052005-12-31	Free cash flow	Unavailable	Capital Expenditure: 3784000 Open source
20062006-12-31	Free cash flow	Unavailable	Capital Expenditure: 4978000 Open source
20072007-12-31	Free cash flow	Unavailable	Capital Expenditure: 1920000 Open source
20082008-12-31	Free cash flow	Unavailable	Capital Expenditure: 1206000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

8.2% 2008

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2003-12-31	Liabilities / assets	Not reported	No source recorded
2004-12-31	Liabilities / assets	Not reported	Total Assets: 15597000 Open source
2005-12-31	Liabilities / assets	Not reported	Total Assets: 59460000 Open source
2006-12-31	Liabilities / assets	Not reported	Total Assets: 45892000 Open source
2007-12-31	Liabilities / assets	Not reported	Total Assets: 51299000 Open source
20082008-12-31	Liabilities / assets	8.2%	Total Liabilities: 3444000 Open source Total Assets: 41800000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.77× 2008

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2003-12-31	Current assets / current liabilities	Not reported	No source recorded
2004-12-31	Current assets / current liabilities	Not reported	No source recorded
2005-12-31	Current assets / current liabilities	Not reported	No source recorded
2006-12-31	Current assets / current liabilities	Not reported	Current Liabilities: 2306000 Open source
2007-12-31	Current assets / current liabilities	Not reported	Current Liabilities: 4554000 Open source
20082008-12-31	Current assets / current liabilities	10.77×	Current Assets: 31751000 Open source Current Liabilities: 2949000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2003 2003-01-01 – 2003-12-31	−USD 2.3 million Exact value Exact value: -2301000 USD 2003-01-01 – 2003-12-31: -2301000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUCRYST Pharmaceuticals Corp. · 2003-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Net Income: -2301000 USD Concept: fundies:NetIncome Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ANetIncome&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2301000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-06-000214.txt#8821 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	USD 1.27 million Exact value Exact value: 1265000 USD 2003-01-01 – 2003-12-31: 1265000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUCRYST Pharmaceuticals Corp. · 2003-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Capital Expenditure: 1265000 USD Concept: fundies:CapitalExpenditure Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ACapitalExpenditure&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1265000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-06-000214.txt#9041 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.
2004 2004-01-01 – 2004-12-31	USD 1.35 million Exact value Exact value: 1348000 USD 2004-01-01 – 2004-12-31: 1348000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUCRYST Pharmaceuticals Corp. · 2004-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Net Income: 1348000 USD Concept: fundies:NetIncome Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ANetIncome&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:NetIncome: 1348000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-07-000236.txt#9242 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	USD 1.82 million Exact value Exact value: 1817000 USD 2004-01-01 – 2004-12-31: 1817000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUCRYST Pharmaceuticals Corp. · 2004-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Capital Expenditure: 1817000 USD Concept: fundies:CapitalExpenditure Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ACapitalExpenditure&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1817000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-06-000214.txt#9041 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.
2005 2005-01-01 – 2005-12-31	−USD 2.64 million Exact value Exact value: -2641000 USD 2005-01-01 – 2005-12-31: -2641000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUCRYST Pharmaceuticals Corp. · 2005-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Net Income: -2641000 USD Concept: fundies:NetIncome Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ANetIncome&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2641000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-08-000171.txt#20550 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	USD 3.78 million Exact value Exact value: 3784000 USD 2005-01-01 – 2005-12-31: 3784000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUCRYST Pharmaceuticals Corp. · 2005-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Capital Expenditure: 3784000 USD Concept: fundies:CapitalExpenditure Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ACapitalExpenditure&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3784000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-06-000214.txt#9041 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.
2006 2006-01-01 – 2006-12-31	−USD 10.5 million Exact value Exact value: -10499000 USD 2006-01-01 – 2006-12-31: -10499000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUCRYST Pharmaceuticals Corp. · 2006-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Net Income: -10499000 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ANetIncome&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10499000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#20548 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	USD 4.98 million Exact value Exact value: 4978000 USD 2006-01-01 – 2006-12-31: 4978000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUCRYST Pharmaceuticals Corp. · 2006-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Capital Expenditure: 4978000 USD Concept: fundies:CapitalExpenditure Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ACapitalExpenditure&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4978000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#21448 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.
2007 2007-01-01 – 2007-12-31	−USD 4.02 million Exact value Exact value: -4021000 USD 2007-01-01 – 2007-12-31: -4021000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUCRYST Pharmaceuticals Corp. · 2007-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Net Income: -4021000 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ANetIncome&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4021000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#20548 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	USD 1.92 million Exact value Exact value: 1920000 USD 2007-01-01 – 2007-12-31: 1920000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUCRYST Pharmaceuticals Corp. · 2007-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Capital Expenditure: 1920000 USD Concept: fundies:CapitalExpenditure Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ACapitalExpenditure&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1920000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#21448 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.
2008 2008-01-01 – 2008-12-31	−USD 2.97 million Exact value Exact value: -2971000 USD 2008-01-01 – 2008-12-31: -2971000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUCRYST Pharmaceuticals Corp. · 2008-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Net Income: -2971000 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2971000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#20548 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	USD 1.21 million Exact value Exact value: 1206000 USD 2008-01-01 – 2008-12-31: 1206000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUCRYST Pharmaceuticals Corp. · 2008-12-31 NUCRYST Pharmaceuticals Corp. (edgar:1344674) Capital Expenditure: 1206000 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T19:37:09Z Snapshot: 623dad53a28dd64a986a3f40b6b1e55f5c147601cd110483cd54ebd012a04e1a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1344674/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1206000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1344674/0001130319-09-000093.txt#21448 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

19 filings · 0 latest values · 0 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001344674, 1344674, edgar:1344674

NUCRYST Pharmaceuticals Corp.

Latest fiscal year

Revenue

Operating margin

Trailing twelve months

Net income

Company performance

What changed year over year

Revenue

Net income

Capital expenditure

Where revenue goes

2008 2008-01-01 – 2008-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation